SynthesisBMC gastroenterology2024
Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.
Synthesis in BMC gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Adjunctive linaclotide improves bowel cleansing and patient experience in polyethylene glycol-based bowel preparation.Scientific reports · 2026Pooled it
- Effects of low-dose medium-chain triglycerides on bowel habit outcomes in Japanese adults prone to constipation: a randomized, double-blind, LCT-controlled crossover trial.Frontiers in nutrition · 2026Trial
- Symptom Terminology Normalization in Traditional Chinese Medicine: Development and Evaluation of a 2-Stage Deep Learning Framework Based on Fine-Grained Semantic Classification.JMIR medical informatics · 2026Article
- The mechanisms and management of fecal incontinence in geriatric neurological diseases.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Review
- Colon Capsule Endoscopy-Measured Colonic Transit Time Is Associated with Frailty in Older Adults.Medicina (Kaunas, Lithuania) · 2026Article
- Impact of Constipation on Quality of Life, Work Productivity, and Treatment Practices: Findings from the CONNECT Web-Based Survey.Digestion · 2026Article
- Ileal bile acid transporter inhibitors for chronic constipation in the elderly.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia.Journal of neurogastroenterology and motility · 2026Article
- Cost-utility analysis of treatment strategies for chronic constipation in Japan.Journal of gastroenterology · 2026Article
- Socioeconomic value of treatments for chronic idiopathic constipation in Japan.BMC gastroenterology · 2025Article
- Assessment of Lubiprostone as an Adjunct Therapy for Bowel Preparation in Colonoscopy: A Meta-Analysis of Randomized Controlled Trials.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Diabetic gastroenteropathy: a pan-alimentary complication.Diabetologia · 2025Review
- A multicenter, postmarketing surveillance of elobixibat in patients with chronic constipation in Japan: A final analysis report.SAGE open medicine · 2025Article
- Cistanche deserticola polysaccharide alleviates constipation by regulating intestinal barrier function and intestinal microbiota and their metabolites.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo comprehensively evaluate the efficacy, safety, patient symptoms, and quality-of-life (QoL) of lubiprostone, linaclotide, and elobixibat as treatment for chronic constipation (CC).
designSystematic literature review (SLR) and meta-analysis (MA). Literature searches were conducted on PubMed and Embase using the Ovid platform.
methodsSLR including randomized controlled trials (RCTs) and observational studies was conducted to identify the overall efficacy and safety of lubiprostone, linaclotide, and elobixibat. Thereafter, MA was performed using only RCTs. The number needed to treat (NNT) and number needed to harm (NNH) analyses were additionally conducted. PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was efficacy regarding change in spontaneous bowel movements. Secondary outcomes included safety, constipation-related symptoms, and QoL.
resultsTwenty-four studies met the inclusion criteria for the SLR: 17 RCTs, 4 observational studies, and 3 single-arm trials. Feasibility assessment for the MA resulted in 14 studies available for safety data analysis, and 8 available for efficacy analysis, respectively. Three drugs showed similar efficacy in the MA and NNT analysis. However, the NNH analysis revealed distinct safety profiles: lubiprostone, linaclotide, and elobixibat were linked to the highest risk of nausea, diarrhea, and abdominal pain, respectively.
conclusionThe current study provides an updated overview of the efficacy, safety, patient symptoms, and QoL of the three drugs with different mechanisms of action for CC treatment.The findings could help physicians adopt an individualized approach for treating patients with CC in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.